Natera, Inc. $NTRA Shares Sold by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. cut its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 28.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,700 shares of the medical research company’s stock after selling 3,800 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Natera were worth $4,009,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of NTRA. BlackRock Inc. purchased a new stake in shares of Natera during the second quarter worth approximately $2,962,770,000. Aberdeen Group plc increased its holdings in Natera by 26,462.7% in the third quarter. Aberdeen Group plc now owns 1,398,794 shares of the medical research company’s stock valued at $578,136,000 after buying an additional 1,393,528 shares during the last quarter. Bank of America Corp DE acquired a new stake in Natera in the second quarter valued at $199,960,000. Legal & General Group Plc acquired a new position in shares of Natera during the 2nd quarter worth about $150,143,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Natera during the 2nd quarter worth about $149,278,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Trading Down 5.8%

Shares of NTRA stock opened at $273.08 on Friday. The business’s 50 day moving average is $375.51 and its two-hundred day moving average is $272.97. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41.

Natera (NASDAQ:NTRA – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Natera had a negative net margin of 5.66% and a negative return on equity of 8.61%. The firm had revenue of $793.98 million during the quarter, compared to analyst estimates of $707.54 million. During the same period in the prior year, the firm posted ($0.64) earnings per share. The business’s quarterly revenue was up 34.1% compared to the same quarter last year. On average, research analysts predict that Natera, Inc. will post -1.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Canaccord Genuity Group raised their price objective on shares of Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, October 19th. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a report on Friday, October 16th. Morgan Stanley raised their price target on Natera from $355.00 to $435.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Piper Sandler reaffirmed an “overweight” rating and set a $363.50 price target on shares of Natera in a research report on Friday, November 6th. Finally, Wells Fargo & Company increased their price objective on Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $396.93.

Get Our Latest Research Report on NTRA

Insiders Place Their Bets

In other news, CFO Michael Brophy sold 470 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $391.49, for a total transaction of $184,000.30. Following the transaction, the chief financial officer directly owned 45,779 shares of the company’s stock, valued at $17,922,020.71. This represents a 1.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,419 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $409.77, for a total transaction of $1,401,003.63. Following the completion of the sale, the insider owned 101,323 shares of the company’s stock, valued at $41,519,125.71. This trade represents a 3.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 47,056 shares of company stock worth $17,760,989 in the last ninety days. 5.05% of the stock is owned by insiders.

Natera Profile

(Free Report)

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

Recommended Stories

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.